2 lucky number today

2 lucky number today Blackstone-backed International Gemological Institute sets price band for Rs 4,225 crore IPOChloe Cole, a detransitioner and activist, slammed the 'irresponsible doctors' for the 'incredible disservice' they have done to children like her, while speaking to Fox News Digital. In oral aruments, Supreme Court justices discussed the high-profile, first-of-its-kind case involving transgender medical treatment for children. Tennessee Attorney General Jonathan Skrmetti, the lawmaker at the center of the suit against the Biden administration, told Fox News Digital that over the next few months, the justices will be "thinking a lot about the case." When asked whether he ever foresaw himself in such a high-profile legal matter, he said, "not remotely." "I do think the fact that there's so much disagreement weighs in favor of our side," Skrmetti said in a phone interview. "This is an area where the court really shouldn't come in and pick a winner. The data is still very underdeveloped." SOTOMAYOR COMPARES TRANS MEDICAL 'TREATMENTS' TO ASPIRIN IN QUESTION ABOUT SIDE EFFECTS DURING ORAL ARGUMENTS Activists hold a rally outside the Supreme Court building in Washington, D.C., as the court hears oral arguments in the transgender treatments case U.S. v. Skrmetti on Dec. 4, 2024. (Fox News Digital) "All the research that both sides point to is unresolved," Skrmetti said. "This is an unsettled area of science, and in situations like that, the best way to resolve it is through the democratic process. Our legislators appropriate people to deal with that uncertainty and make the call for each individual state." The justices appeared divided on Wednesday after oral arguments, and the three appointed by former President Trump could be the key to deciding the socially divisive question. Justices Brett Kavanaugh and Amy Coney Barrett asked tough questions of both sides, and Justice Neil Gorsuch did not speak during the marathon public session. For its part, the Supreme Court is considering whether the Equal Protection Clause, which ensures equal treatment under the law for similarly situated individuals, bars states from prohibiting medical providers from administering puberty blockers and hormones to help minors transition to a different gender. The case is U.S. v. Skrmetti and is challenging Tennessee's state law which bans medical procedures for minors. Outside the court, hundreds of demonstrators rallied both for and against gender transition treatments for children. One of those rally-goers, detransitioner and activist Chloe Cole, told Fox News Digital in an interview that if the justices oppose the ban on trans medical treatments, "it's going to make things a lot more difficult on legislative fronts in terms of protecting our children and our youth." 'THE PENDULUM IS SWINGING': EXPERTS WEIGH IN ON HISTORIC SCOTUS TRANSGENDER CASE AMID ORAL ARGUMENTS Detransitioner and activist Chloe Cole outside the Supreme Court building during oral arguments in the U.S. v. Skrmetti case on Dec. 4, 2024. (Fox News Digital) "If we want to create a precedent for other states, for first this law, to be upheld in courts and for other states to be upheld as well, we have to do this now," Cole said. Cole, who detransitioned at the age of 16, told Fox News Digital that doctors had done an "incredible disservice" to her at a young age by helping her transition in the first place. "I'm never going to even have a chance at nursing my children with what God gave me," Cole said. "An incredible disservice has been done to me by these irresponsible doctors who knew better. They knew better than to do this to a child. They still chose to do it. But they messed with the wrong kid, and I am going to make sure there is never another child in America who is abused in the same way I was ever again." The court's decision could have sweeping implications, potentially shaping future legal battles over transgender issues, such as access to bathrooms and school sports participation. A decision is expected by July 2025. "So if the court puts a thumb on the scale and says that the courts could be second-guessing state governments on these issues, I think you're going to see an inhibited debate, and we've seen this happen before in other contexts where democracy is subverted by judges who step a little too far into the policy arena, and that ultimately hurts the country," Skrmetti said. "It de-legitimates the government," he added. "It makes people feel alienated from the political process. The alternative is it stays open to our democratic system of resolving disagreements, and you'll see a lot of debate, and different states will go in different directions, and over time, we'll have better research, and people will have a chance to debate this extensively, and that's just the better way to come to a resolution on such a hot button issue where the Constitution is silent." The Justices' decision may also influence broader debates about whether sexual orientation and gender identity qualify as protected classes under civil rights laws, akin to protections for race and national origin. SUPREME COURT WEIGHS TRANSGENDER YOUTH TREATMENTS IN LANDMARK CASE A court sketch depicts the United States Supreme Court hearing oral arguments regarding abortion rights on Wednesday, April 24, 2024. (William J Hennessy Jr.) CLICK HERE TO GET THE FOX NEWS APP When asked whether Skrmetti believes the incoming Trump administration could persuade the justices one way in the case, he said, "It's ultimately up to the court how they want to handle that." Trump promised during his campaign he would outlaw transgender medical procedures for minors and open the doorway to allowing individuals to sue medical providers for conducting them. "But there is a path there for them to continue this, and I think it's important that we get clarity soon, because there are so many cases involving these issues, and the lower courts have not been consistent and are looking for guidance, and it would do everyone good to have a more clear answer to the state of the law," he said. Fox News Digital's Shannon Bream and Bill Mears contributed to this report. Jamie Joseph is a writer who covers politics. She leads Fox News Digital coverage of the Senate.Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE Amgen

Jarvis Moss, Jonas Sirtautas lead Radford past Bucknell 74-70 in OTVance takes on a more visible transition role, working to boost Trump's most contentious picks

Benzinga Bulls And Bears: Tesla, GameStop, Nvidia, Bitcoin, And Dogecoin Analyst Flags $1.30-$1.50 As Key Target

Patriots' coaches enter bye week confident Drake Maye can be a franchise quarterbackWhat happens when 'The Simpsons' join 'Monday Night Football'? Find out during Bengals-CowboysCelularity Inc. Announces Receipt of Nasdaq Notification

Money Research Collective’s editorial team solely created this content. Opinions are their own, but compensation and in-depth research determine where and how companies may appear. Many featured companies advertise with us. How we make money . By Marc Guberti MONEY RESEARCH COLLECTIVE December 5, 2024 Investing in assets can put you in a better position by the time you’re ready to retire. While stocks and real estate have received plenty of attention over the years, gold remains a reliable investment that has been around for thousands of years. It’s an essential resource for many industries, is a medium of exchange and serves as a safe-haven asset during geopolitical unrest or periods of market volatility. Gold is a hedge against inflation and can thrive during economic uncertainty. That last advantage is a key distinction that separates it from stocks and real estate. However, physical gold doesn’t produce yield like dividend stocks or cash flow like investment properties. Fortunately, it’s still possible to use precious metals to generate retirement income. This guide will explain several ways to use gold for retirement income. Open a gold IRA A gold individual retirement account — or gold IRA — allows you to accumulate physical precious metals in a tax-advantaged account. You won’t have to worry about gold storage, as the IRA’s custodian will handle it. You can then cash out on your gold holdings when you need to cover living expenses. The IRS sets limits for how much you can contribute to an IRA, whether it’s a conventional or gold IRA. If you make the maximum contribution to a gold IRA, you can’t contribute to another IRA. The maximum contribution for traditional and Roth IRAs is currently capped at $7,000 per year for those age 49 and younger. The IRS raises this limit periodically, but you can make catch-up contributions if you are 50 years or older. Catch-up contributions allow you to invest an additional $1,000 into your IRA each year. Anyone can open a Roth IRA, but your modified adjusted gross income must be below $146,000 to contribute the full amount. Investors who earn too much for a Roth IRA can use the backdoor method to fund it. This involves moving funds from a traditional IRA — which doesn’t have income restrictions — to a Roth IRA. Some gold IRA providers give you the flexibility to set up traditional and Roth IRAs. Learn more by reading our guide to the best gold IRA companies . Invest in gold stocks and gold ETFs Gold stocks are easier to buy and manage than physical gold. You also wouldn’t need a separate IRA just for gold investments. However, gold stocks can underperform the precious metal due to several factors. For instance, Newmont Corp. — the world’s largest gold mining company — has only seen its stock gain 13% over the past five years, failing to keep pace with gold prices , which have gained more than 70% during the same period. Varying financial performances and opportunities result in gold stocks having different results than physical gold. Investors have to trust that a company will make good business decisions instead of leaning exclusively on the long-term reliability of gold. However, gold stocks have an edge with liquidity, especially if you want to receive dividends. For example, Newmont has a dividend yield above 2%, and it’s not the only gold stock that offers a good dividend. Some people prefer to avoid the complexities of converting physical gold into cash and opt for dividends and stocks instead. Some gold exchange-traded funds also produce yield, which help generate income in retirement. These gold ETFs hold baskets of gold mining companies, whereas some gold ETFs are backed by physical gold and do not pay dividends. Similar to gold stocks, gold ETFs have also lagged the gains of physical gold. For example, while the VanEck Gold Miners ETF has a dividend that yields around 1.34%, it gained 41.55% over the past five years compared to the 70% return for physical gold. Buy physical gold and exchange it when necessary It takes more time to buy physical gold than buying a stock, including finding a reputable and trustworthy gold dealer . Physical gold isn’t as liquid, and you are responsible for storage (and optional gold insurance , as well). However, a key advantage of physical gold is that you claim full ownership of the asset. While gold ETFs and IRAs give you exposure to gold and better liquidity, buying the physical asset gives you the most control. Some people value having control over the asset instead of trusting a custodian, gold miner or fund manager. Luckily, physical gold commands a lot of value without taking up much space. A kilogram of gold is smaller than most iPhones, and an ounce of gold is about half the size of an iPhone. It’s easy to hide and move gold around if needed, but it’s still good to find professional storage and get it insured in case something happens. Physical gold should continue to gain value due to inflation. Then, you can sell your gold bars and coins when you need extra retirement funds. Should gold be a part of your retirement strategy? Putting all of your eggs in one basket is very risky, and that’s why many experts recommend diversifying your portfolio. Gold can be a valuable part of the mix, as its returns aren’t correlated to the stock market. The prices of precious metals can hold steady or gain value when stocks and real estate enter corrections. And while expert opinions on gold vary, many agree that investors shouldn’t allocate more than 5-10% of their portfolio to the precious metal. This amount of exposure provides a good buffer against inflation while allowing you to allocate funds to other asset classes. IRAs are attractive options for gold investors who want to capitalize on tax benefits while growing their portfolios. Conventional IRAs reduce your present taxable income, while Roth IRAs shield you from taxes on your distributions and capital gains. While those types of accounts can hold gold-backed equities like stocks and ETFs, only gold IRAs can hold precious metals. Investors should assess their long-term goals and financial situations before accumulating gold.Olga Evtushkova SNOW's Rally Has Been Overly Fast & Furious - Expensive Valuations Offer Minimal Margin Of Safety We previously covered Snowflake (NYSE: SNOW ) in October 2024, discussing the stock's ongoing meltdown, attributed to the decelerating topline growth trend and Analyst’s Disclosure: I/we have a beneficial long position in the shares of NVDA, TSM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.